SUPPLEMENT
Q1 2023 — Financial disclosures
Q1 2023PDF · 9 pages982 KB
Merck & Co., Inc. Financial Highlights Package First Quarter 2023 Table of Contents Table 1: GAAP P&L..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q23........................3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q22.........................4 Table 3: Sales – Current Year and Prior Year by Quarter ...............5 Table 3a: Sales – U.S. / Ex- U.S. 1Q23.............................................6 Table 3b: Sales – Pharmaceutical Geographic Split .........................7 Table 4: Other (Income) Expense ....................................................8 -- 1 of 9 -- Sales 14,487 $ 15,901 $ -9% Costs, Expenses and Other Cost of sales 3,926 5,380 -27% Selling, general and administrative 2,479 2,323 7% Research and development 4,276 2,576 66% Restructuring costs 67 53 26% Other (income) expense, net 89 708 -87% Income Before Taxes 3,650 4,861 -25% Income Tax Provision 825 554 Net Income 2,825 4,307 -34% Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 (3) Net Income Attributable to Merck & Co., Inc. 2,821 $ 4,310 $ -35% Earnings per Common Share Assuming Dilution 1.11 $ 1.70 $ -35% Average Shares Outstanding Assuming Dilution 2,551 2,537 Tax Rate 22.6% 11.4% 1Q22 GAAP % Change 1Q23 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 1 -- 2 of 9 -- Sales 14,487 $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ -9% Costs, Expenses and Other Cost of sales 3,926 5,380 4,216 3,934 3,881 17,411 -27% Selling, general and administrative 2,479 2,323 2,512 2,520 2,687 10,042 7% Research and development 4,276 2,576 2,798 4,399 3,775 13,548 66% Restructuring costs 67 53 142 94 49 337 26% Other (income) expense, net 89 708 438 429 (75) 1,501 -87% Income Before Taxes 3,650 4,861 4,487 3,583 3,513 16,444 -25% Income Tax Provision 825 554 538 330 495 1,918 Net Income 2,825 4,307 3,949 3,253 3,018 14,526 -34% Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 (3) 5 5 1 7 Net Income Attributable to Merck & Co., Inc. 2,821 $ 4,310 $ 3,944 $ 3,248 $ 3,017 $ 14,519 $ -35% Earnings per Common Share Assuming Dilution 1.11 $ 1.70 $ 1.55 $ 1.28 $ 1.18 $ 5.71 $ -35% Average Shares Outstanding Assuming Dilution 2,551 2,537 2,540 2,542 2,548 2,542 Tax Rate 22.6% 11.4% 12.0% 9.2% 14.1% 11.7% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 1Q 2023 1Q 1Q 2Q 3Q 4Q Full Year 2022 Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2 -- 3 of 9 -- First Quarter Cost of sales 3,926 $ 545 29 574 3,352 $ Selling, general and administrative 2,479 20 1 21 2,458 Research and development 4,276 10 10 4,266 Restructuring costs 67 67 67 - Other (income) expense, net 89 15 (429) 573 (3) 159 (70) Income Before Taxes 3,650 (590) (97) 429 (573) (831) 4,481 Income Tax Provision (Benefit) 825 (105) (4) (18) (4) 95 (4) (60) (4) (88) 913 Net Income 2,825 (485) (79) 334 (513) (743) 3,568 Net Income Attributable to Merck & Co., Inc. 2,821 (485) (79) 334 (513) (743) 3,564 Earnings per Common Share Assuming Dilution 1.11 $ (0.19) (0.03) 0.13 (0.20) (0.29) 1.40 $ Tax Rate 22.6% 20.4% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FIRST QUARTER 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, reflect a $37 million loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Certain Other Items (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. 3 -- 4 of 9 -- First Quarter Cost of sales 5,380 $ 680 46 726 4,654 $ Selling, general and administrative 2,323 50 21 71 2,252 Research and development 2,576 22 7 29 2,547 Restructuring costs 53 - 53 53 - Other (income) expense, net 708 (115) 684 569 139 Income Before Taxes 4,861 (637) (127) (684) (1,448) 6,309 Income Tax Provision (Benefit) 554 (155) (3) (22) (3) (152) (3) (329) 883 Net Income 4,307 (482) (105) (532) (1,119) 5,426 Net Income Attributable to Merck & Co., Inc. 4,310 (482) (105) (532) (1,119) 5,429 Earnings per Common Share Assuming Dilution 1.70 $ (0.19) (0.04) (0.21) (0.44) 2.14 $ Tax Rate 11.4% 14.0% Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP MERCK & CO., INC. FIRST QUARTER 2022 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2b 4 -- 5 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2023 2022 1Q 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $14,487 $15,901 $14,593 $14,959 $13,830 $59,283 -9 -5 PHARMACEUTICAL 12,721 14,107 12,756 12,963 12,180 52,005 -10 -6 Oncology Keytruda 5,795 4,809 5,252 5,426 5,450 20,937 20 24 Alliance Revenue – Lynparza (2) 275 266 275 284 292 1,116 3 8 Alliance Revenue – Lenvima (2) 232 227 231 202 216 876 2 5 Alliance Revenue – Reblozyl (3) 43 52 33 39 41 166 -19 -19 Welireg 42 18 27 38 40 123 128 128 Vaccines (4) Gardasil / Gardasil 9 1,972 1,460 1,674 2,294 1,470 6,897 35 43 ProQuad / M-M-R II / Varivax 528 470 578 668 526 2,241 12 14 RotaTeq 297 216 173 256 139 783 38 42 Vaxneuvance 106 5 12 16 138 170 * * Pneumovax 23 96 173 153 131 145 602 -44 -40 Vaqta 40 36 35 64 39 173 12 13 Hospital Acute Care Bridion 487 395 426 423 441 1,685 23 27 Prevymis 129 94 103 114 118 428 38 44 Primaxin 80 58 64 63 54 239 37 48 Dificid 65 52 66 77 67 263 25 25 Noxafil 60 57 60 62 58 238 5 14 Zerbaxa 50 30 46 43 49 169 66 70 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 99 72 98 88 82 341 38 38 Adempas (6) 59 61 63 57 57 238 -3 5 Virology Lagevrio 392 3,247 1,177 436 825 5,684 -88 -87 Isentress / Isentress HD 123 158 147 161 167 633 -23 -20 Neuroscience Belsomra 56 69 69 62 59 258 -19 -9 Immunology Simponi 180 186 181 173 166 706 -3 2 Remicade 51 61 53 49 44 207 -15 -10 Diabetes (7) Januvia 551 779 756 717 561 2,813 -29 -26 Janumet 329 454 476 417 353 1,700 -28 -24 Other Pharmaceutical (8) 584 602 528 603 583 2,319 -3 1 ANIMAL HEALTH 1,491 1,482 1,467 1,371 1,230 5,550 1 5 Livestock 849 832 826 829 814 3,300 2 8 Companion Animals 642 650 641 542 416 2,250 -1 2 Other Revenues (9) 275 312 370 625 420 1,728 -12 -22 *200% or greater (7) Total Diabetes sales were $950 million in the first quarter of 2023 and $1,305 million in the first quarter of 2022. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $51 million in the first quarter of 2023 and $114 million in the first quarter of 2022. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $3,133 million in the first quarter of 2023 and $2,481 million in the first quarter of 2022. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. 5 -- 6 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 1Q 2023 1Q 2022 % Change 1Q 2023 1Q 2022 % Change 1Q 2023 1Q 2022 % Change TOTAL SALES (1) $14,487 $15,901 -9 $6,659 $7,339 -9 $7,828 $8,563 -9 PHARMACEUTICAL 12,721 14,107 -10 6,117 6,773 -10 6,604 7,334 -10 Oncology Keytruda 5,795 4,809 20 3,485 2,779 25 2,310 2,030 14 Alliance Revenue – Lynparza (2) 275 266 3 142 141 1 133 125 6 Alliance Revenue – Lenvima (2) 232 227 2 153 156 -2 79 71 11 Alliance Revenue – Reblozyl (3) 43 52 -19 30 27 11 12 25 -51 Welireg 42 18 128 41 18 122 1 - Vaccines (4) Gardasil / Gardasil 9 1,972 1,460 35 416 418 - 1,556 1,042 49 ProQuad / M-M-R II / Varivax 528 470 12 421 371 14 107 99 8 RotaTeq 297 216 38 180 175 3 117 41 185 Vaxneuvance 106 5 * 94 5 * 13 * Pneumovax 23 96 173 -44 40 118 -66 56 55 2 Vaqta 40 36 12 30 29 4 10 7 48 Hospital Acute Care Bridion 487 395 23 276 195 41 210 199 6 Prevymis 129 94 38 54 40 37 75 54 39 Primaxin 80 58 37 4 1 * 76 58 32 Dificid 65 52 25 62 49 25 3 3 12 Noxafil 60 57 5 14 10 47 46 48 -3 Zerbaxa 50 30 66 27 18 49 23 12 92 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 99 72 38 83 71 17 16 1 * Adempas (6) 59 61 -3 59 61 -3 Virology Lagevrio 392 3,247 -88 -2 1,523 -100 394 1,723 -77 Isentress / Isentress HD 123 158 -23 52 61 -16 71 97 -27 Neuroscience Belsomra 56 69 -19 16 20 -21 40 48 -17 Immunology Simponi 180 186 -3 180 186 -3 Remicade 51 61 -15 51 61 -15 Diabetes (7) Januvia 551 779 -29 271 325 -17 280 454 -38 Janumet 329 454 -28 56 63 -11 272 391 -30 Other Pharmaceutical (8) 584 602 -3 172 160 8 414 443 -7 ANIMAL HEALTH 1,491 1,482 1 482 473 2 1,010 1,009 - Livestock 849 832 2 174 171 2 676 660 2 Companion Animals 642 650 -1 308 302 2 334 349 -4 Other Revenues (9) 275 312 -12 60 93 -35 214 220 -3 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $950 million in the first quarter of 2023 and $1,305 million in the first quarter of 2022. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $51 million in the first quarter of 2023 and $114 million in the first quarter of 2022. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $3,133 million in the first quarter of 2023 and $2,481 million in the first quarter of 2022. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 9 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 2023 2022 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q TOTAL PHARMACEUTICAL $12,721 $14,107 $12,756 $12,963 $12,180 $52,005 -10 United States 6,117 6,773 5,726 6,620 5,871 24,989 -10 % Pharmaceutical Sales 48.1% 48.0% 44.9% 51.1% 48.2% 48.1% Europe (1) 2,326 3,309 2,677 2,427 2,494 10,906 -30 % Pharmaceutical Sales 18.3% 23.5% 21.0% 18.7% 20.5% 21.0% China 1,694 1,113 1,355 1,419 1,216 5,102 52 % Pharmaceutical Sales 13.3% 7.9% 10.6% 10.9% 10.0% 9.8% Japan 737 965 1,092 653 832 3,542 -24 % Pharmaceutical Sales 5.8% 6.8% 8.6% 5.0% 6.8% 6.8% Asia Pacific (other than China and Japan) 703 786 854 702 691 3,034 -11 % Pharmaceutical Sales 5.5% 5.6% 6.7% 5.4% 5.7% 5.8% Latin America 470 435 453 511 472 1,871 8 % Pharmaceutical Sales 3.7% 3.1% 3.6% 3.9% 3.9% 3.6% Eastern Europe/Middle East/Africa 381 450 339 360 320 1,469 -15 % Pharmaceutical Sales 3.0% 3.2% 2.7% 2.8% 2.6% 2.8% Canada 141 189 166 166 158 678 -25 % Pharmaceutical Sales 1.1% 1.3% 1.3% 1.3% 1.3% 1.3% Other 152 87 94 105 126 414 75 % Pharmaceutical Sales 1.2% 0.6% 0.6% 0.9% 1.0% 0.8% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q23 1Q22 Interest income (112) $ (7) $ Interest expense 242 243 Exchange losses 61 39 (Income) loss from investments in equity securities, net (1) (450) 708 Net periodic defined benefit plan (credit) cost other than service cost (115) (121) Other, net 463 (154) Total 89 $ 708 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --